Polycystic ovary syndrome and metabolic syndrome share cardiometabolic risks due to insulin resistance, necessitating early diagnosis and long-term follow-up to prevent serious co-morbidities.
Highlights the importance of recognizing and managing the shared cardiometabolic risks between PCOS and metabolic syndrome beyond reproductive age.
By virtue of insulin resistance being the common etiology for polycystic ovary syndrome (PCOS) and metabolic syndrome, the cardiometabolic risks of these two syndromes are shared. The usual concerns of a PCOS patient are cosmetic or reproductive. However, there are more serious concerns past the reproductive age. Early treatment of insulin resistance, hypertension and hyperlipidemia reduces the long-term risk. This review highlights the unhealthy association of metabolic syndrome with PCOS and emphasizes the importance of early diagnosis, patient education and long-term follow-up beyond the reproductive age into menopause to prevent the long-term serious co-morbidities.
Shah et al. (2015) conducted a review in Polycystic ovary syndrome (PCOS) and metabolic syndrome. Early treatment of insulin resistance, hypertension and hyperlipidemia was evaluated. Polycystic ovary syndrome and metabolic syndrome share cardiometabolic risks due to insulin resistance, necessitating early diagnosis and long-term follow-up to prevent serious co-morbidities.